DE2102245A1 - Verfahren zur Herstellung von Antisera - Google Patents
Verfahren zur Herstellung von AntiseraInfo
- Publication number
- DE2102245A1 DE2102245A1 DE19712102245 DE2102245A DE2102245A1 DE 2102245 A1 DE2102245 A1 DE 2102245A1 DE 19712102245 DE19712102245 DE 19712102245 DE 2102245 A DE2102245 A DE 2102245A DE 2102245 A1 DE2102245 A1 DE 2102245A1
- Authority
- DE
- Germany
- Prior art keywords
- antisera
- antigens
- antigen
- cells
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 17
- 239000000427 antigen Substances 0.000 claims description 42
- 108091007433 antigens Proteins 0.000 claims description 42
- 102000036639 antigens Human genes 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 28
- 210000002966 serum Anatomy 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 18
- 241001465754 Metazoa Species 0.000 claims description 14
- 210000004698 lymphocyte Anatomy 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 230000000961 alloantigen Effects 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- 238000002523 gelfiltration Methods 0.000 claims description 5
- 238000005063 solubilization Methods 0.000 claims description 5
- 230000007928 solubilization Effects 0.000 claims description 5
- 108090000526 Papain Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 229940055729 papain Drugs 0.000 claims description 4
- 235000019834 papain Nutrition 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000005345 coagulation Methods 0.000 claims description 2
- 230000015271 coagulation Effects 0.000 claims description 2
- 230000000527 lymphocytic effect Effects 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000012264 purified product Substances 0.000 claims description 2
- 238000005199 ultracentrifugation Methods 0.000 claims description 2
- 239000000575 pesticide Substances 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 238000005194 fractionation Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 description 24
- 238000002649 immunization Methods 0.000 description 21
- 238000010521 absorption reaction Methods 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 239000000284 extract Substances 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000000719 anti-leukaemic effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 231100000355 lymphocytotoxic Toxicity 0.000 description 2
- 230000001391 lymphocytotoxic effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000004141 dimensional analysis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- -1 picin Proteins 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- AGDSCTQQXMDDCV-UHFFFAOYSA-M sodium;2-iodoacetate Chemical compound [Na+].[O-]C(=O)CI AGDSCTQQXMDDCV-UHFFFAOYSA-M 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2854/70A GB1291134A (en) | 1970-01-21 | 1970-01-21 | A process for the production of mammal cell anti-sera |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2102245A1 true DE2102245A1 (de) | 1971-08-12 |
Family
ID=9747225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712102245 Pending DE2102245A1 (de) | 1970-01-21 | 1971-01-19 | Verfahren zur Herstellung von Antisera |
Country Status (8)
| Country | Link |
|---|---|
| CA (1) | CA953215A (OSRAM) |
| CH (1) | CH530793A (OSRAM) |
| DE (1) | DE2102245A1 (OSRAM) |
| ES (1) | ES387472A1 (OSRAM) |
| FR (1) | FR2081446B1 (OSRAM) |
| GB (1) | GB1291134A (OSRAM) |
| NL (1) | NL7100777A (OSRAM) |
| ZA (1) | ZA71167B (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS548714A (en) * | 1977-06-16 | 1979-01-23 | Saikin Kagaku Kenkiyuushiyo Kk | Production of specific antiserum |
| AU519008B2 (en) * | 1978-04-20 | 1981-11-05 | D. L McCOLLESTER | Immunotherapy of neoplastic disease |
-
1970
- 1970-01-21 GB GB2854/70A patent/GB1291134A/en not_active Expired
-
1971
- 1971-01-12 ZA ZA710167A patent/ZA71167B/xx unknown
- 1971-01-19 DE DE19712102245 patent/DE2102245A1/de active Pending
- 1971-01-20 NL NL7100777A patent/NL7100777A/xx unknown
- 1971-01-20 CH CH81871A patent/CH530793A/fr not_active IP Right Cessation
- 1971-01-20 CA CA103,179A patent/CA953215A/en not_active Expired
- 1971-01-20 ES ES387472A patent/ES387472A1/es not_active Expired
- 1971-01-20 FR FR7101841A patent/FR2081446B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2081446B1 (OSRAM) | 1975-04-18 |
| CA953215A (en) | 1974-08-20 |
| CH530793A (fr) | 1972-11-30 |
| FR2081446A1 (OSRAM) | 1971-12-03 |
| ES387472A1 (es) | 1974-01-01 |
| GB1291134A (en) | 1972-09-27 |
| NL7100777A (OSRAM) | 1971-07-23 |
| ZA71167B (en) | 1972-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3586440T2 (de) | Zur diagnose von menschlichem magen- oder brustkrebs zu verwendender monoklonaler antikoerper. | |
| EP0021152B1 (de) | Verfahren zur immunologischen Bestimmung von Basalmembranmaterial, hierfür geeignete Basalmembranfragmente und Verfahren zu deren Herstellung, bzw. Gewinnung | |
| DE2049515A1 (de) | Impfstoff gegen Virushepatitis | |
| DE2648458A1 (de) | Reagenz zur diagnose von krebs, dessen herstellung und anwendung | |
| EP0279460A1 (de) | Virusantigen, Verfahren zu seiner Gewinnung und Anwendung in Diagnose und Therapie (Impfstoff) | |
| DE3019847A1 (de) | Verfahren zur herstellung von menschlichem interferon und es enthaltende mittel | |
| DE69220939T2 (de) | Gegengift immunsera | |
| DE2102245A1 (de) | Verfahren zur Herstellung von Antisera | |
| DE3413339A1 (de) | Gegen pilze der gattung candida gerichtete antikoerper | |
| DE3424640A1 (de) | Verfahren zur gewinnung und/oder bestimmung von humanspezifischem interferon im blut | |
| DE3785795T2 (de) | Monoklonale anti-menschliche magenkrebs-antikoerper. | |
| DE2742835A1 (de) | Antigenfraktionen von schistosoma mansoni-eiern, geeignet fuer die untersuchung von schistosomiasis | |
| CH639667A5 (de) | Verfahren zur herstellung von peptidkomplexen aus dns-haltigen organismen. | |
| DE3410694A1 (de) | Gewebeprotein pp(pfeil abwaerts)2(pfeil abwaerts)(pfeil abwaerts)1(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung | |
| DE2333740A1 (de) | Antigen, verfahren zu dessen isolierung, bestimmung und dessen verwendung | |
| DE2243237A1 (de) | Nachweis der immunreaktion gegenueber krebs | |
| DE2815758C3 (de) | Peptidkomplexe aus DNS-haltigen Organismen | |
| DE2353035B2 (de) | Verfahren zur Stabilisierung menschlicher oder tierischer Körperflüssigkeiten oder pflanzlicher Extrakte | |
| DE2533183C3 (de) | Verfahren zum Herstellen gereinigter Immunglobuline | |
| DE2728802C2 (de) | Verfahren zum Herstellen eines antischistosomen immunologischen Mittels | |
| DE3913438A1 (de) | Verfahren zum herstellen einer immunitaetsgedaechtniszellsuspension | |
| DE68913793T2 (de) | Ein von einem Human-Human-Hybridom abgeleiteter monoklonaler Antikörper und dessen Verwendung. | |
| DE2205897C3 (de) | Verfahren zur Herstellung von Antithymozytenserum | |
| DE4204132A1 (de) | Aufbereitung fuer die diagnose und/oder gewinnung von vakzinen fuer eine immuntherapie | |
| DE2606257A1 (de) | Recognine |